Notable Runner: Is Dynavax Technologies Corporation’s Fuel Running Low? The Stock Reaches Yearly Low Today

Notable Runner: Is Dynavax Technologies Corporation's Fuel Running Low? The Stock Reaches Yearly Low Today

The stock of Dynavax Technologies Corporation (NASDAQ:DVAX) hit a new 52-week low and has $9.18 target or 10.00% below today’s $10.20 share price. The 5 months bearish chart indicates high risk for the $376.34M company. The 1-year low was reported on Oct, 17 by Barchart.com. If the $9.18 price target is reached, the company will be worth $37.63 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 256,808 shares traded hands. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 40.44% since March 14, 2016 and is downtrending. It has underperformed by 46.05% the S&P500.

Analysts await Dynavax Technologies Corporation (NASDAQ:DVAX) to report earnings on November, 3. They expect $-0.74 earnings per share, up 9.76% or $0.08 from last year’s $-0.82 per share. After $-0.75 actual earnings per share reported by Dynavax Technologies Corporation for the previous quarter, Wall Street now forecasts -1.33% EPS growth.

Dynavax Technologies Corporation (NASDAQ:DVAX) Ratings Coverage

Out of 2 analysts covering Dynavax Technologies (NASDAQ:DVAX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dynavax Technologies has been the topic of 4 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The rating was downgraded by RBC Capital Markets on Thursday, April 28 to “Sector Perform”. The firm earned “Hold” rating on Wednesday, August 12 by Zacks. RBC Capital Markets initiated Dynavax Technologies Corporation (NASDAQ:DVAX) rating on Monday, November 30. RBC Capital Markets has “Outperform” rating and $48 price target. The firm has “Neutral” rating given on Wednesday, April 27 by JP Morgan.

According to Zacks Investment Research, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.”

Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.04, from 1.06 in 2016Q1. The ratio worsened, as 18 funds sold all Dynavax Technologies Corporation shares owned while 34 reduced positions. 10 funds bought stakes while 43 increased positions. They now own 31.67 million shares or 4.27% less from 33.08 million shares in 2016Q1.
Millennium Management Lc accumulated 84,506 shares or 0% of the stock. The New York-based Glenhill Advisors Limited Liability has invested 1.36% in Dynavax Technologies Corporation (NASDAQ:DVAX). Susquehanna Group Llp reported 89,798 shares or 0% of all its holdings. Citadel Advsr Lc last reported 28,713 shares in the company. Lombard Odier Asset Management (Usa) Corp has 245,728 shares for 0.43% of their US portfolio. The Massachusetts-based Boston Prtnrs has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Lord Abbett And Communications Ltd Liability Corp last reported 273,362 shares in the company. Metropolitan Life Ins Ny last reported 28,014 shares in the company. Orbimed Advsr Limited Liability Company holds 0.37% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 2.40 million shares. Morgan Stanley holds 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX) for 290,285 shares. The Pennsylvania-based Pnc Services has invested 0% in Dynavax Technologies Corporation (NASDAQ:DVAX). Nationwide Fund Advsrs has invested 0% of its portfolio in Dynavax Technologies Corporation (NASDAQ:DVAX). Claar Ltd last reported 125,000 shares in the company. Zurcher Kantonalbank (Zurich Cantonalbank) owns 856 shares or 0% of their US portfolio. Perceptive Advsr Ltd Liability reported 2,499 shares or 0% of all its holdings.

Insider Transactions: Since May 12, 2016, the stock had 2 insider buys, and 0 selling transactions for $57,940 net activity. Shares for $15,120 were bought by Janssen Robert on Thursday, May 12. The insider Gray Eddie bought 2,750 shares worth $42,820.

More recent Dynavax Technologies Corporation (NASDAQ:DVAX) news were published by: Investorplace.com which released: “Dynavax Technologies Corporation (DVAX) Steals Back Gains on Pending Heplisav …” on October 03, 2016. Also Investorplace.com published the news titled: “Dynavax Technologies Corporation (DVAX) Injected With 20%-Plus Gains” on September 06, 2016. Seekingalpha.com‘s news article titled: “Will Dynavax’ Hepsilav-B Ever Get Approved?” with publication date: October 14, 2016 was also an interesting one.

DVAX Company Profile

Dynavax Technologies Corporation (Dynavax), incorporated on November 6, 2000, is a clinical-stage biopharmaceutical company. The Firm uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. The Company’s development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). The Company’s lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. The Company’s SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. The Company’s advanced inflammatory disease candidate is AZD1419. The Company’s pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment